BNTC

BNTC

USD

Benitec Biopharma Inc. Common Stock

$15.710+0.380 (2.479%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$15.330

उच्च

$15.770

कम

$14.550

मात्रा

0.13M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

412.4M

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

0.05M

एक्सचेंज

NCM

मुद्रा

USD

52-सप्ताह रेंज

कम $9.1वर्तमान $15.710उच्च $17.15

संबंधित समाचार

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and raises the price target from $28 to $35.

और देखें
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35
Analyst Upgrades

Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22

Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $20 to $22.

और देखें
Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22
GlobeNewswire

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted

और देखें
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
GlobeNewswire

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based

और देखें
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
GlobeNewswire

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines

और देखें
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।